Japan Biobanks Market Report 2023 to 2030

Japan Biobanks Market Analysis

$ 3999

The Japan Biobanks Market was valued at $4,770.05 Mn in 2023 and is predicted to grow at a CAGR of 9.30% from 2023 to 2030, to $8,889.24 Mn by 2030. The key drivers of this industry include government support, increasing demand for biomedical research, and a high prevalence of diseases. The industry is primarily dominated by players such as Thermo Fisher Scientific, Merck KGaA, QIAGEN, and Tecan Group among others.

ID: IN10JPHS058 CATEGORY: Healthcare Services GEOGRAPHY: Japan AUTHOR: Aashwi Mehta

Buy Now

Japan Biobanks Market Executive Summary

The Japan Biobanks Market was valued at $4,770.05 Mn in 2023 and is predicted to grow at a CAGR of 9.30% from 2023 to 2030, to $8,889.24 Mn by 2030.

A biobank is a curated collection of mainly human biological samples and related data systematically organized for research purposes. These facilities play a crucial role in medical research, supporting various contemporary studies such as genomics and personalized medicine. The types of samples and information gathered vary based on each biobank's specific objectives. For instance, some biobanks focus on specific diseases like cancer, while others are population-based, comprising samples and data from individuals within a particular demographic or geographic area.

As of November 2023, the Tohoku Medical Megabank Project in Japan has amassed over 1 Mn tubes of plasma and serum, alongside significant quantities of DNA and other biological materials. Similarly, by March 31, 2023, Bio Bank Japan has collected 453,875 DNA samples and 111,890 serum samples from patients with 51 different diseases. The market is driven by significant factors like government support, increasing demand for biomedical research, and a high prevalence of diseases. However, regulatory challenges, ethical concerns, and complex logistics restrict the growth and potential of the market.

Prominent players in this field include Thermo Fisher Scientific, Merck KGaA, QIAGEN, and Tecan Group among others.

Japan Biobanks Market Report 2023 to 2030

Market Dynamics

Market Growth Drivers

Government Support: The Japanese government is strongly backing biobanking through funding and policy initiatives to advance personalized medicine and genomic research. Projects like Tohoku Medical Megabank and Bio Bank Japan are crucial for large-scale data collection and analysis, boosting the biobank sector's infrastructure and resources.

Increasing Demand for Biomedical Research: The increasing focus on biomedical research, including drug development, cancer studies, and chronic disease research, is driving demand for biobanks. This surge in interest fuels the biobank market in Japan by highlighting the need for extensive biological data to support advanced research and therapeutic innovation.

High Prevalence of Diseases: The estimated prevalence of non-communicable diseases in Japan includes 12.2% for diabetes mellitus and 20.9% for hypertension. These high rates drive the biobank market by underscoring the need for extensive research and data collection to better understand and combat these widespread conditions.

Market Restraints

Regulatory Challenges: Regulations and ethical guidelines governing the collection, storage, and use of biological samples can impede the development and growth of biobanks. These stringent requirements can delay the establishment of new biobanks and complicate their expansion, thereby limiting market progress.

Ethical Concerns: Ethical concerns related to the collection and use of biological samples, such as privacy issues, consent challenges, and potential misuse of genetic information, pose a significant market restraint. These issues can create public hesitancy and skepticism, which may hinder the growth and establishment of biobanks in Japan.

Complex Logistics: Handling and organizing the extensive volumes of biological samples and their associated data can be both complex and costly. This logistical burden represents a market restraint for biobanks in Japan, as it demands significant resources and efficient management systems to ensure smooth operations.

Regulatory Landscape and Reimbursement Scenario

The Ministry of Health, Labour and Welfare (MHLW) is essential in overseeing biobanks in Japan, setting guidelines and policies for the ethical handling of biological samples. It supports initiatives such as the National Center Biobank Network (NCBN), which links biobanks at national centers for advanced medicine, ensuring adherence to ethical and legal standards. Additionally, the Japan Agency for Medical Research and Development (AMED) contributes to biobank efforts through funding and collaborative projects.

Competitive Landscape

Key Players

Here are some of the major key players in the Japan Biobanks Market:

Thermo Fisher Scientific
Merck KGaA
QIAGEN
Tecan Group
Becton, Dickinson and Company
STEMCELL Technologies
Avantor
Promega Corporation
Hamilton Company
Azenta Life Sciences

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Japan Biobanks Market Segmentation

By Product and Service

Equipment
Consumables
Services

By Sample Type

Blood Products
Human Tissues
Nucleic Acids
Others

By Application

Regenerative Medicine
Life Science Research
Clinical Research
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.